ITRI vs REGN · P/E 13, rev $2.44B vs P/E 14, rev $14.34B
Itron Inc (ITRI) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Itron Inc (ITRI) is a scientific & technical instruments company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported ITRI revenue for 2024-12-31 was $2.44B. Net income was $241.1M. Revenue was up 12.3% from 2023-12-31 to 2024-12-31. ITRI currently screens at market cap $3.64B and trailing P/E 13.1.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ITRI currently screens at market cap $3.64B and trailing P/E 13.1. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ITRI and REGN stock pages for the full models.
Not investment advice.